More Phase 3 disappointment in Alzheimer’s disease
Alzheimer's underdog Accera revealed Tuesday that its 413-patient trial of AC-1204 failed to reach its stated endpoints.
The Phase 3 Alzheimer’s company few have heard of
Accera will soon deliver Phase 3 data on Alzheimer's disease, so why has nobody heard of them?
presented by
Everything You Need to Know About Who Accredits Health Plans for Mental Health Parity Compliance
Who accredits health plans for mental health parity compliance? Learn about the only organization that offers this program to ensure your members get equitable care.